HER3 has been involved in intrinsic resistance to MEK inhibition also in KRAS mutant lung and colon cancers [36] and it has been found that MEK inhibition by selumatenib results in MYC-dependent transcriptional up-regulation of HER3, which is responsible for intrinsic drug resistance. The gene discussed is KRAS; the disease is malignant colon neoplasm.